<- Go Home
Metacrine, Inc.
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is based in San Ramon, California.
Market Cap
$25.5M
Volume
1.7M
Cash and Equivalents
$52.8M
EBITDA
-$36.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$19.5M
Profit Margin
N/A
52 Week High
$0.59
52 Week Low
$0.30
Dividend
N/A
Price / Book Value
0.67
Price / Earnings
-0.60
Price / Tangible Book Value
0.67
Enterprise Value
-$13.5M
Enterprise Value / EBITDA
0.38
Operating Income
-$36.1M
Return on Equity
90.72%
Return on Assets
-36.86
Cash and Short Term Investments
$52.8M
Debt
$13.8M
Equity
$37.1M
Revenue
N/A
Unlevered FCF
-$20.2M
Sector
Biotechnology
Category
N/A